213 related articles for article (PubMed ID: 21730105)
1. The FOXE1 and NKX2-1 loci are associated with susceptibility to papillary thyroid carcinoma in the Japanese population.
Matsuse M; Takahashi M; Mitsutake N; Nishihara E; Hirokawa M; Kawaguchi T; Rogounovitch T; Saenko V; Bychkov A; Suzuki K; Matsuo K; Tajima K; Miyauchi A; Yamada R; Matsuda F; Yamashita S
J Med Genet; 2011 Sep; 48(9):645-8. PubMed ID: 21730105
[TBL] [Abstract][Full Text] [Related]
2. Genotype Analyses in the Japanese and Belarusian Populations Reveal Independent Effects of rs965513 and rs1867277 but Do Not Support the Role of FOXE1 Polyalanine Tract Length in Conferring Risk for Papillary Thyroid Carcinoma.
Nikitski AV; Rogounovitch TI; Bychkov A; Takahashi M; Yoshiura KI; Mitsutake N; Kawaguchi T; Matsuse M; Drozd VM; Demidchik Y; Nishihara E; Hirokawa M; Miyauchi A; Rubanovich AV; Matsuda F; Yamashita S; Saenko VA
Thyroid; 2017 Feb; 27(2):224-235. PubMed ID: 27824288
[TBL] [Abstract][Full Text] [Related]
3. FOXE1 association with differentiated thyroid cancer and its progression.
Penna-Martinez M; Epp F; Kahles H; Ramos-Lopez E; Hinsch N; Hansmann ML; Selkinski I; Grünwald F; Holzer K; Bechstein WO; Zeuzem S; Vorländer C; Badenhoop K
Thyroid; 2014 May; 24(5):845-51. PubMed ID: 24325646
[TBL] [Abstract][Full Text] [Related]
4. The synergic effect of BRAF
Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z
Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763
[TBL] [Abstract][Full Text] [Related]
5. Age at diagnosis and gender modify the risk of 9q22 and 14q13 polymorphisms for papillary thyroid carcinoma.
Kula D; Kalemba M; Puch Z; Polańska J; Świerniak M; Rusinek D; Żebracka-Gala J; Kowalska M; Handkiewicz-Junak D; Kowal M; Tyszkiewicz T; Piasna E; Czarniecka A; Pawlaczek A; Krajewska J; Szpak-Ulczok S; Jarząb B
Endokrynol Pol; 2017; 68(3):283-289. PubMed ID: 28660995
[TBL] [Abstract][Full Text] [Related]
6. Are the SNPs of NKX2-1 associated with papillary thyroid carcinoma in the Han population of Northern China?
Ai L; Yu Y; Liu X; Wang C; Shi J; Sun H; Yu Q
Front Med; 2014 Mar; 8(1):113-7. PubMed ID: 24452548
[TBL] [Abstract][Full Text] [Related]
7. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.
Elisei R; Viola D; Torregrossa L; Giannini R; Romei C; Ugolini C; Molinaro E; Agate L; Biagini A; Lupi C; Valerio L; Materazzi G; Miccoli P; Piaggi P; Pinchera A; Vitti P; Basolo F
J Clin Endocrinol Metab; 2012 Dec; 97(12):4390-8. PubMed ID: 23066120
[TBL] [Abstract][Full Text] [Related]
8. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.
Xing M; Alzahrani AS; Carson KA; Viola D; Elisei R; Bendlova B; Yip L; Mian C; Vianello F; Tuttle RM; Robenshtok E; Fagin JA; Puxeddu E; Fugazzola L; Czarniecka A; Jarzab B; O'Neill CJ; Sywak MS; Lam AK; Riesco-Eizaguirre G; Santisteban P; Nakayama H; Tufano RP; Pai SI; Zeiger MA; Westra WH; Clark DP; Clifton-Bligh R; Sidransky D; Ladenson PW; Sykorova V
JAMA; 2013 Apr; 309(14):1493-501. PubMed ID: 23571588
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH
Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112
[TBL] [Abstract][Full Text] [Related]
10. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
11. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.
Kurtulmus N; Duren M; Ince U; Cengiz Yakicier M; Peker O; Aydın O; Altiok E; Giray S; Azizlerli H
Endocrine; 2012 Oct; 42(2):404-10. PubMed ID: 22426956
[TBL] [Abstract][Full Text] [Related]
12. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.
Guerra A; Zeppa P; Bifulco M; Vitale M
Thyroid; 2014 Feb; 24(2):254-9. PubMed ID: 23806056
[TBL] [Abstract][Full Text] [Related]
13. Associations of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma.
Park AY; Son EJ; Kim JA; Youk JH; Park YJ; Park CS; Chang HS
PLoS One; 2014; 9(10):e110868. PubMed ID: 25337709
[TBL] [Abstract][Full Text] [Related]
14. Increase in Papillary Thyroid Cancer Incidence Is Accompanied by Changes in the Frequency of the BRAF V600E Mutation: A Single-Institution Study.
Kowalska A; Walczyk A; Kowalik A; Pałyga I; Trybek T; Kopczyński J; Kajor M; Chrapek M; Pięciak L; Chłopek M; Góźdź S; Kamiński G
Thyroid; 2016 Apr; 26(4):543-51. PubMed ID: 26889698
[TBL] [Abstract][Full Text] [Related]
15. The FOXE1 locus is a major genetic determinant for radiation-related thyroid carcinoma in Chernobyl.
Takahashi M; Saenko VA; Rogounovitch TI; Kawaguchi T; Drozd VM; Takigawa-Imamura H; Akulevich NM; Ratanajaraya C; Mitsutake N; Takamura N; Danilova LI; Lushchik ML; Demidchik YE; Heath S; Yamada R; Lathrop M; Matsuda F; Yamashita S
Hum Mol Genet; 2010 Jun; 19(12):2516-23. PubMed ID: 20350937
[TBL] [Abstract][Full Text] [Related]
16. Association between BRAF V600E mutation and regional lymph node metastasis in papillary thyroid carcinoma.
Lu J; Gao J; Zhang J; Sun J; Wu H; Shi X; Teng L; Liang Z
Int J Clin Exp Pathol; 2015; 8(1):793-9. PubMed ID: 25755776
[TBL] [Abstract][Full Text] [Related]
17. False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma.
Paek SH; Kim BS; Kang KH; Kim HS
World J Surg Oncol; 2017 Nov; 15(1):202. PubMed ID: 29132392
[TBL] [Abstract][Full Text] [Related]
18. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
[TBL] [Abstract][Full Text] [Related]
19. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF
Nasirden A; Saito T; Fukumura Y; Hara K; Akaike K; Kurisaki-Arakawa A; Asahina M; Yamashita A; Tomomasa R; Hayashi T; Arakawa A; Yao T
Virchows Arch; 2016 Dec; 469(6):687-696. PubMed ID: 27718012
[TBL] [Abstract][Full Text] [Related]
20. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.
Kim SJ; Lee KE; Myong JP; Park JH; Jeon YK; Min HS; Park SY; Jung KC; Koo do H; Youn YK
World J Surg; 2012 Feb; 36(2):310-7. PubMed ID: 22190222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
